A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer: A Korean Gynecologic Oncologic Group study

Hanbyoul Cho, Byung Ho Nam, Seok Mo Kim, Chi Heum Cho, Byoung Gie Kim, Hee Sug Ryu, Soon Beom Kang, Jae Hoon Kim

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Purpose A phase 2 study was completed by the Korean Gynecologic Oncologic Group to evaluate the efficacy and toxicity of concurrent chemoradiation with weekly paclitaxel in patients with high-risk endometrial cancer. Methods and Materials Pathologic requirements included endometrial endometrioid adenocarcinoma stages III and IV. Radiation therapy consisted of a total dose of 4500 to 5040 cGy in 5 fractions per week for 6 weeks. Paclitaxel 60 mg/m 2 was administered once weekly for 5 weeks during radiation therapy. Results Fifty-seven patients were enrolled between January 2006 and March 2008. The median follow-up time was 60.0 months (95% confidence interval [CI], 51.0-58.2). All grade 3/4 toxicities were hematologic and usually self-limited. There was no life-threatening toxicity. The cumulative incidence of intrapelvic recurrence sites was 1.9% (1/52), and the cumulative incidence of extrapelvic recurrence sites was 34.6% (18/52). The estimated 5-year disease-free and overall survival rates were 63.5% (95% CI, 50.4-76.5) and 82.7% (95% CI, 72.4-92.9), respectively. Conclusions Concurrent chemoradiation with weekly paclitaxel is well tolerated and seems to be effective for high-risk endometrioid endometrial cancers. This approach appears reasonable to be tested for efficacy in a prospective, randomized controlled study.

Original languageEnglish
Pages (from-to)140-146
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume90
Issue number1
DOIs
Publication statusPublished - 2014 Sep 1

Bibliographical note

Funding Information:
This study was made possible by the help of the following subinvestigators: St. Mary's Hospital (Seog Nyeon Bae, Woong Shick Ahn), Cheil General Hospital and Women's Healthcare Center (Ki-Heon Lee), Kyungpook National University Hospital (Yoon Soon Lee), Kyung Hee University Medical Center (Min Hyung Jung), Keimyung University Dongsan Medical Center (Soon-Do Cha), Korea University Guro Hospital (Jae-Kwan Lee), National Cancer Center (Sang-Yoon Park), Dong-A University Hospital (Moon Seok Cha), Seoul National University Hospital (Noh-Hyun Park), Samsung Medical Center (Duk-Soo Bae, Jeong-Won Lee), Soonchunhyang University Chunan Hospital (Dong-Han Bae), Ajou University Hospital (Suk-Joon Chang), Severance Hospital (Young Tae Kim, Sunghoon Kim, Sang Wun Kim), Yeungnam University Medical Center (Seung Ho Lee), Asan Medical Center (Yong Man Kim), Korea Cancer Center Hospital (Sang-Young Ryu), Hanyang University Seoul Hospital (Joong Sub Choi).

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer: A Korean Gynecologic Oncologic Group study'. Together they form a unique fingerprint.

Cite this